Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

7.0K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
7.0K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.6K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?

Clinical genitourinary cancer·2026
Same author

ProBIOPSY: A Multidisciplinary International Consensus on Standards for Prostate Biopsy.

European urology·2026
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026
Same author

Chemoradiotherapy for anal canal cancers: Does the choice of boost technique matter?

Journal of contemporary brachytherapy·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: Apr 18, 2026

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

7.4K

[Metastatic hormone-sensitive prostate cancer].

Gwenaelle Gravis1, Naji Salem2, Jochen Walz3

  • 1Institut Paoli-Calmettes, oncologie médicale, centre de recherche en cancérologie de Marseille, UMR1068 Inserm, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France.

Bulletin Du Cancer
|January 23, 2015
PubMed
Summary

Hormone-sensitive metastatic prostate cancer (HSMPC) treatment focuses on castration, with chemotherapy improving survival in high-volume cases. Prognostic factors like bone and visceral involvement significantly impact patient outcomes.

Keywords:
Cancer de la prostateCancer de la prostate métastatiqueCastration-sensitiveDocetaxelDocétaxelHormonosensibleM1Metastatic prostate cancerNon-castrateProstate cancerSensible à la castration

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.1K

Related Experiment Videos

Last Updated: Apr 18, 2026

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

7.4K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

15.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.1K

Area of Science:

  • Oncology
  • Urology

Background:

  • Metastatic prostate cancer can present as hormone-sensitive (HSMPC), either initially or after local treatment without prior castration.
  • Castration remains the primary treatment, with initiation typically based on symptomatic disease progression.

Purpose of the Study:

  • To review current treatment strategies for HSMPC.
  • To discuss prognostic factors influencing survival.
  • To explore emerging therapies and their potential in HSMPC.

Main Methods:

  • Literature review of studies on hormone-sensitive metastatic prostate cancer.
  • Analysis of clinical and biological prognostic factors.
  • Evaluation of treatment modalities including castration, chemotherapy, and bone-targeted agents.

Main Results:

  • Docetaxel chemotherapy combined with castration significantly improves survival in patients with high-volume HSMPC.
  • Bone localization and visceral involvement are key clinical prognostic factors.
  • Clodronic acid shows survival benefit in HSMPC, unlike other bone agents which are effective in castration-resistant disease.

Conclusions:

  • Optimal timing and modality of castration require further investigation.
  • New hormonal therapies targeting the androgen receptor are being evaluated for HSMPC.
  • The goal is to enhance survival, improve quality of life, and delay progression to castration-resistant disease.